Important Safety InformationPrescribing Information

The Pharmacy Times® Basal Insulin Challenge is sponsored by Novo Nordisk.

LEADERBOARD

Unsure of an answer? Click this icon for additional information regarding Tresiba®, including important counseling tips.

Welcome to the Pharmacy Times®
Basal Insulin CHALLENGE.

Your task is to watch an informational video and answer 10 questions about how, as a pharmacist, you can help your patients with diabetes get started on Tresiba®.

If you answer all the questions correctly, you will receive a certificate recognizing your expertise.

Do you have what it takes to master the Basal Insulin Challenge? Watch the video and answer all 10 questions correctly and faster than your colleagues, and your name could appear in the Top Ten Performances Leaderboard. Good luck!

1

Watch the
VIDEO

2

Answer the
QUESTIONS

3

Complete the
CHALLENGE

Question 1

Which of the following accurately states the indication for Tresiba® 100 U/mL and 200 U/mL?

ATresiba® is a once-daily, long-acting insulin analog indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

BTresiba® is a once-daily, long-acting insulin indicated to improve glycemic control and to treat diabetic ketoacidosis in patients 3 years and older with diabetes mellitus.

CTresiba® is a rapid- and long- acting insulin indicated to improve post-meal glycemic control in patients 3 years and older with diabetes mellitus.

DTresiba® is a rapid-acting insulin analog indicated to improve glycemic control in patients 18 years and older with diabetes mellitus.

Question 2

In the video, Philip Woodham, MD, noted that Tresiba® was his preferred treatment choice for insulin-naïve patients. True or False?

True

False

Question 3

Tresiba® is available in 3 administration options. True or False?

True

False

Question 4

Which of the following accurately states the contraindications of Tresiba®?

ATresiba® is contraindicated during episodes of hypoglycemia.

BTresiba® is contraindicated in patients with hypersensitivity to Tresiba® or one of its excipients.

CTresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients.

DNone of the above.

Question 5

With a 1:1 dose conversion, adults already taking insulin can start on the same unit dose of Tresiba® as their current basal insulin and administer their injection of Tresiba® at any time of day. True or False?

True

False

Question 6

Which of the following can result from repeated injections in the same injection site?

ALocalized cutaneous amyloidosis at the injection site.

BHyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis.

CHypoglycemia has been reported with a sudden change to an unaffected injection site.

DAll of the above

Question 7

Which of the following is NOT a correct counseling point to communicate with patients who have been prescribed Tresiba®?

AAdvise patients to check the label before each injection to avoid mix-ups between Tresiba® and any other insulins they may be taking.

BAdvise patients never to share their FlexTouch® pen, needle, or syringes, to avoid transmitting diseases.

CAdvise patients on how to select an injection site and how to inject their insulin, as well as how to monitor for injection site reactions.

DAdvise patients that hyperglycemia is the most common adverse reaction of insulin therapy and may be life-threatening.

Question 8

What is the recommended time between dose increases of Tresiba®?

A8 hours

B3 to 4 days

C3 to 4 weeks

D8 weeks

Question 9

Which of the following is incorrect regarding the appropriate storage of Tresiba®?

ATresiba® vials should be stored in the original packaging and protected from light.

BUnused Tresiba® products should be refrigerated until use and may be used up until their labeled expiration date, at which point they should not be used.

COnce opened and in use, Tresiba® can be kept at room temperature (below 86°F) or be refrigerated (36°F to 46°F) for up to 8 weeks, after which it should not be used.

DTresiba® should be kept in the freezer.

Question 10

Pharmacists can recommend that patients visit NovoCare.com to find out their coverage and cost in minutes and enroll in the Tresiba® Instant Savings Card. With the Tresiba® Instant Savings Card, patients may be eligible for which of the following?

AThey can pay as little as [$5] per [30-day] supply of Tresiba® Flextouch® U-100, U-200, and the U-100 vial, for up to [24 months].

BThey can receive a free box of Novo Nordisk Needles.

CThey can receive automatic enrollment in the Cornerstones4Care® patient support program, including access to the online Diabetes Health Coach for eligible patients.

DAll of the above.

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Welcome

Video

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Complete

Hide

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
    • Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
    • Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
    • Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Please click here for Prescribing Information

Cornerstones4Care®, FlexTouch®, NovoFine®, and Tresiba® are registered trademarks of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

© 2020 Novo Nordisk All rights reserved. US20TSM00053 June 2020

Novo Nordisk<sup>®</sup> Logo